CURE’s kidney cancer page is an extensive resource of cancer information featuring the latest kidney cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on kidney cancer.
January 28th 2017
Vaccines are currently being tested in their potential to improve immunotherapy responses for patients with renal cell carcinoma.
January 26th 2017
Elizabeth Plimack, M.D., discusses an update on the CheckMate-025 trial, comparing Opdivo to Afinitor in patients with metastatic renal cell carcinoma.
January 21st 2017
David F. McDermott, M.D., is optimistic about combination regimens shaping the treatment landscape for renal cell carcinoma.
January 12th 2017
After the approvals of agents in the second-line setting, researchers are now turning to improving the frontline treatment of kidney cancer.
December 19th 2016
Will the newly approved kidney cancer treatments eventually end up in the frontline setting? Expert Chung-Han (Joe) Lee, M.D., weighs in.
December 14th 2016
Obesity can negatively affect cancer treatment outcomes, trigger disease recurrence and shorten longevity. Organized weight loss programs and exercise can help patients protect themselves.
December 5th 2016
Immunotherapy combinations are on the horizon for the treatment of renal cell carcinoma, Robert J. Motzer, M.D., says.
December 3rd 2016
Melanoma should not be considered to be in a "special category" that responds well to immunotherapy, according to Christian M. Capitini, M.D., assistant professor of Pediatrics at the University of Wisconsin.
November 30th 2016
A panel of experts recently discussed the evolving field of immunotherapy for solid tumor types.
November 28th 2016
TKIs will continue to shape the landscape of kidney cancer treatment, Robert A. Figlin, M.D., F.A.C.P., says.
November 17th 2016
Cabometyx was proved to be superior to Sutent, reducing rates of disease progression or death for patients with metastatic RCC, according to a recent trial.
October 11th 2016
In a recent phase 2 trial, Cabometyx showed longer progression-free survival than Sutent in patients with metastatic kidney cancer.
October 9th 2016
After going through the "Dark Ages," we're approaching the "Golden Age" of kidney cancer care, with more options available than ever, says James Hsieh.
October 3rd 2016
There have been some exciting advances in using immunotherapy to treat GU malignancies such as kidney and bladder cancer. CURE sat down with Elizabeth Plimack, M.D. to discuss them.
September 23rd 2016
The treatment landscape for advanced kidney cancer has changed dramatically over the past few years, with several targeted drugs and an immunotherapy approved by the FDA.
September 23rd 2016
Ten years ago, patients with advanced RCC had very few treatment options, yet today, there are multiple therapeutic strategies and more in the pipeline for this not-very-common tumor type, writes our editor-in-chief, Debu Tripathy.
September 21st 2016
While many new treatment options have been introduced for kidney cancer in recent years, the question of how to sequence them is still being debated.
September 16th 2016
A recent study showed a correlation between higher body mass index and survival in some patients with kidney cancer.
September 14th 2016
Most people don't know much about kidney cancer at the time of their diagnosis. The Kidney Cancer Association wants to change that.
August 15th 2016
Jorge Garcia offers insight about the benefits of Cabometyx and the drug's impact on RCC.
August 13th 2016
Randy F. Sweis talks to CURE about the future of treatment for GU cancers.
August 4th 2016
A recent phase 3 study showed that Sutent extended disease-free survival for patients with renal cell carcinoma.
July 6th 2016
Sumanta K. Pal weighs in on a new drug combination that is showing promise for patients with RCC who progressed on Cabometyx (cabozantinib) and Opdivo (nivolumab).
June 24th 2016
The treatment paradigm in renal cell carcinoma (RCC) has expanded over recent months to include three practice-changing agents in the second-line setting.
June 22nd 2016
Not only is Opdivo changing the way RCC is being treated, but the immunotherapy is also here to stay, according to David F. McDermott.
June 10th 2016
Previously treated patients with advanced renal cell carcinoma saw a higher overall survival rate with Cabometyx when compared to those on Afinitor, according to a phase 3 study.
June 6th 2016
In the longest follow-up of an anti-PD-1 immunotherapy in RCC, about one-third of the patients treated with single-agent Opdivo are still alive four and five years later.
June 3rd 2016
What are the next steps for immunotherapy in RCC? CURE spoke with Mark Ball to find out.
May 14th 2016
After a phase 2 study, Lenvima and Afinitor gained FDA approval for the treatment of renal cell carcinoma.
May 9th 2016
“This is a small-site, single-arm study, but these preliminary data are encouraging,” says lead study author Roberto Pili. “It suggests that this combination of an HDAC inhibitor can induce a greater benefit with an immunotherapy — in this case, IL-2.”